Periodic Reporting for period 1 - CADISS (A medical device for the selective dissection of pathological tissues and fibrosis)
Periodo di rendicontazione: 2019-12-01 al 2020-03-31
The CADISS System is a novel method of dissection in general surgery based on the combination of mechanical surgery instruments with the topical deposition of a drug, which selectively facilitates separation of pathological tissues without using cutting instruments.
This feasibility study confirms the feasibility of the project in all technical, commercial and financial aspects. The main activities to be carried out include the development of new surgical tools, carrying out the required regulatory processes and scaling up production. We estimate an investment of €9.3M with €3.2M from the Grant support of the Accelerator Pilot SME Instrument and €6.1M from the equity finance under the EIC.
COMMERCIAL FEASIBILITY. We have assessed our Freedom to Operate and the regulatory procedure in the EU and the USA. Our commercial analysis includes analysis of the market, end-users, drivers and barriers. We have also defined our commercial strategy.
FINANCIAL FEASIBILITY. We have performed the funding needs validation, delineated the cost structure and 5 years business projections. We will generate a big turnover and profit, reaching breakeven in 2023.
The Feasibility Study confirms the technical feasibility and commercial profitability of our project. Moreover, it shows the novelty of our innovation and the great benefits that would bring to patients and the health sector.